Diabetic nephropathy is one prevalent complication of diabetes leading to a high financial liability for the healthcare system. The manifestation of low but abnormal levels of urine albumin referred to as microalbuminuria is the initial confirmation of nephropathy. The American Diabetes Association recommends annual screening for microalbuminuria in type 1 diabetic patients starting five years after diagnosis. Annual screening for patients with type 2 diabetes mellitus should start at the time of diagnosis. The purpose of this study was to determine if healthcare providers were adhering to the ADA recommendations related to screening for microalbuminuria in patients with diabetes mellitus. Of the 150 charts reviewed, the percentage of charts reflecting a quantitative value of microalbuminuria documented in the charts of patients with type 2 diabetes mellitus once per calendar year was 44.7% (n=67). Efforts should be made to educate healthcare providers about standards of care, which include adhering to the recommended guidelines.Diabetic nephropathy. Clinical Diabetes, 18, 1-15. Golan, L., Birkmeyer, J.D., aamp; Welch, H. (1999). The cost-effectiveness of treating all patients with type 2 diabetes with angio-tension converting enzyme inhibitors. Annals of Internal Medicine, anbsp;...
|Title||:||Screening for Microalbuminuria According to the ADA Guidelines in Patients with Diabetes Mellitus|
|Publisher||:||ProQuest - 2007|